Roland J.W. Meesters, BSc BSc MSc PhD (Lonza Netherlands, Geleen, the Netherlands). Orcid.org/0000-0002-8946-2329
earned his Ph.D. in Bioanalytical Chemistry at Erasmus University Rotterdam in the Netherlands. Dr. Meesters past research activities focused on bioanalytical sciences and he has a specific interest in metabolomics, therapeutic drug monitoring, and PK modeling and in the role of metabolites in biological processes and in diseases. He is a specialist in the development and application of quantitative bioanalytical techniques particularly involving LC in combination with mass spectrometry. At Lonza Netherlands, he is a Scientist and Line Manager of the BioAanalytical Services group focussing on the development and support of Cell and Gene Therapy Development Services.
Jeffery Hackett, MSc PhD D-ABFT CSci CChem FRSC (Forensic Laboratory Division, Office of Chief Medical Examiner, San Francisco, USA).
received from the Royal Society of Chemistry (Grad.RSC), Chartered Chemist (CChem) and Chartered Scientist (CSci) status. He holds a MSc degree in Instrumental Chemical Analysis, and a PhD in Forensic Analytical Toxicology from Liverpool John Moores University. Dr. Hackett is a member of SOFT, TIAFT, and a Fellow of AAFS and as well as a Fellow of the Royal Society of Chemistry. Dr. Hackett’s research interests lie in the area of Solid Phase Extraction (SPE) of drugs/poisons from difficult matrices such as post mortem fluids/tissues and analysis by chromatographic systems coupled to mass spectrometers. In 2014, Dr. Hackett was awarded Diplomate status of the American Board of Forensic Toxicology (D-ABFT).
Irene Panderi BSc PhD, (University of Athens, Athens, Greece). orcid.org/0000-0003-3190-0127
Irene Panderi is a Professor of Pharmaceutical Analysis at the Laboratory of Pharmaceutical Analysis, Faculty of Pharmacy, National and Kapodistrian University of Athens. Irene Panderi is a pharmacist with over 20 years’ experience in leading research in the fields of Pharmaceutical Analysis and Analytical Chemistry developing analytical methods for the analysis of drugs, metabolites and bioactive compounds in pharmaceuticals, cosmeceuticals, biological fluids and human tissues. These methods are applied to clinical testing, toxicology studies, doping control and quality control of drugs. She is also a member of the Scientific Committee on Consumers Safety (SCCS).
Leimin Fan BSc PhD, (RockTown Technology and Service, Libertyville, IL, USA).
obtained his Ph.D. degree of Physical Organic Chemistry from University of Memphis. He has been working in the pharmaceutical industry as an analytical chemist for more than 15 years. His expertise includes peptide purification and analysis, API analysis, stability evaluation, HPLC and LC/MS/MS method development and validation, GLP regulated bioanalysis for non-clinical and clinical studies. In recent years, Dr. Fan has emphasized his research on new technologies and automated processes to improve bioanalysis efficiency. He invented the DMPD (dried matrix on paper disc) technology to improve DBS performance by reduce and eliminate its hematocrit effect.
Lùcia Carrano PhD, (Fondazione Instituto Insubrico Ricerca per La Vita, Gerenzano, Italy).
recieved her PhD in Chemical Sciences at the University of Napoli. Dr Carrano is Principal Scientist at FIIRV, a private research foundation, her research projects concern purification, characterization, novelty evaluation of protein and organic molecules from fermentations broths; evaluation of their potential in programs concerning different therapeutic area; methods development and pharmacokinetic analysis; studies on mechanisms of resistance in antibiotic producers. Dr Carrano tutored on natural products, HTS, data handling, assay development, early phase of drug discovery. She was Contract Professor at the Faculty of Science at the University of Napoli and Viterbo and is recognized as Qualified Person by AIFa and appointed as member of the Chemists Order Disciplinary Council (Lombardia).
Alexander Buko PhD,(Human Metabolome Technologies, Boston, MA, USA).
received his Ph.D. in 1980 from the University of Virginia in protein bioanalytical chemistry using paper electrophoresis and HPLC. He went onto the Bureau of Biologics and Biophysics for four years then moved to Abbott Labs for 18 years leading analytics in metabolomics, proteomics, quantitation and structural characterization of small molecules and proteins using LCMS, NMR, surface microscopy and biophysical technologies. From 2002 to 2012 Alex was Sr. Director Translational Medicine at BiogenIdec responsible for protein analytics, proteomics, metabolomics and quantitative bioanalysis using FTMS, Imaging MS, UV and MS/MS. Currently he is Vice President of Business and Product Development for Human Metabolome Technologies (HMT). Since 2002, HMT has focused on delivering comparative and quantitative metabolic profiling to research communities using CEMS and LCMS.
Sophie Ayciriex MSc PhD, (ANABIO-MS Laboratory, Institute of Analytical Sciences, Villeurbanne, France).
earned her M.Sc. degree in Biochemistry and Structural Biology at the University Paul Sabatier (Toulouse, France). She obtained her european Ph.D. degree in Biochemistry in 2010 at the University Bordeaux Segalen, France. During her PhD fellowship, she investigated the characterization of a novel lysolipid acyltransferase in S. cerevisiae by combining several biochemistry tools and lipidomics. For her first post-doctoral fellowship, she joined the University Paris Descartes – Faculty of Pharmacy (CNRS UMR 8638) in Paris, France. She developed analytic methods for the analysis of sterols and oxysterols by UPLC-ESI-HRMS and conducted lipidomics research in relation with neurodegeneration. She is currently pursuing her postdoc in analytical chemistry, performing shotgun Lipidomics on high-resolution mass spectrometry at Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. System biology of lipid metabolism is one of her main research.
Jennifer Knaack PhD, (Mercer University, Atlanta, GA, USA).
Assistant Professor in the Department of Pharmaceutical Sciences in the College of Pharmacy. She received her Ph.D. in Pharmaceutical Sciences from the University of Southern California where she studied the structure of an intestinal drug transporter. Following her graduate studies, Dr. Knaack was a postdoctoral fellow at Lawrence Livermore National Laboratory where she studied yeast metabolism using accelerator mass spectrometry. Dr. Knaack then spent four years at the Centers for Disease Control and Prevention in Atlanta, GA where she developed novel diagnostic methods for measuring human exposure to organophosphorus nerve agents and paralytic shellfish toxins. Now at Mercer University, Dr. Knaack develops innovative diagnostic methods for measuring exposure to environmental and synthetic toxins. She teaches in several courses including gastrointestinal and renal anatomy, physiology and pharmacology as well as analytical methods and instrumentation.
Rob J. Vreeken PhD, (Discovery Sciences, Janssen Pharmaceutica, Beerse, Belgium). orcid.org/0000-0003-3568-1371
received his Ph.D. from the Free University of Amsterdam (NL). Hereafter, he developed and applied a variety of MS-based techniques for quantitative and qualitative analysis in academic and commercial settings (PD at EPFL (Lausanne, CH) and group leader at KWR (Netherlands Drinking Water Research facility) and TNO (CRO and research institute)). Subsequently, he headed the Waters EU applications, training, demonstration and support organisations. After leading the pharma-unit at Avantium (CRO, Amsterdam, NL) he joined the Netherlands Metabolomics Centre (Leiden Academic Centre for Drug Research, Leiden University, NL) as Assistant Professor to create and direct the Central Lab facility. Next to teaching, he developed novel strategies for e.g. (endogenous) metabolite identification and advanced lipidomics, which were used for biomarker discovery in inflammatory processes. From July 2014 he directs a team at Janssen Pharmaceutica (Johnson & Johnson, Beerse, Belgium) focusing on early stage pathway engagement studies, bio-analysis and biomarker validation.
Xiaobin Xu BSc MSc PhD (Regeneron Pharmaceuticals, Tarrytown, NY, USA).
Xiaobin is a Scientist at Regeneron Pharmaceuticals. He received his B.S. and M.S. in Chemistry from Sichuan University, China. He did his Ph. D. in Prof. Catherine E. Costello’s lab at Boston University, where he focused on proteomics and biological applications of mass spectrometry. At Regeneron, he leads and performs analytical characterization of therapeutic proteins to support pre-clinical and clinical development. In addition, he develops new analytical methods and technologies to better characterize monoclonal antibodies (mAbs). His research interests include mass spectrometry based therapeutic protein/biomarker quantification, hydrogen deuterium exchange mass spectrometry (HDX-MS) and chemical cross-linking mass spectrometry for protein conformation and protein-protein interaction studies, post-translational modifications, top-down mass spectrometry, host cell protein identification and quantification, separation of mAbs and mAb fragments, and bioanalytical method development and validation.
Mu Chen PhD (Frontage Labs, Exton, PA, USA).
Mu Chen obtained his Ph.D. degree in Dr. Jeehiun K. Lee’s research group at Rutgers University, the State University of New Jersey. His Ph.D. research focused on the characterization of novel organic compounds, damaged nucleobases, and RNA oligonucleotides by using analytical methods based on mass spectrometry and LC-MS/MS. In 2014, Mu Chen joined Frontage Labs, a leading CRO company in bioanalysis (Exton, PA). He participated in many research projects in which bioanalytical methods were developed to support pharmaceutical R&D. He is experienced with HPLC separation, mass spectrometry optimization and instrumentation, and pretreatment of biological samples in various matrices, from both theoretical and practical perspectives. His recent interest has also shifted to quantitation of large molecule drugs (oligonucleotides, therapeutic monoclonal antibodies, peptides) by using both immunogenicity and mass spectrometry platforms.
Victoria Samanidou PhD (Aristotle University of Thessaloniki, Thessaloniki, Greece). orcid.org/0000-0002-8493-1106
Dr Victoria Samanidou is a Professor of Analytical Chemistry in the Chemistry Department of the Aristotle University of Thessaloniki (Greece). Her current research activities include: Modern sample preparation techniques used in the development of validated HPLC and GC methods for the determination of inorganic and organic substances in biological samples, pharmaceuticals, forensics and toxicology samples, food, samples of environmental interest. She has published more than 130 original research articles in peer reviewed journals and 50 reviews and chapters in scientific books. H-index 25 (source Scopus May 2016). She is member of editorial board of more than 10 scientific journals and she has reviewed almost 350 manuscripts in more than 80 scientific journals. She was also guest editor in 2 special issues in scientific journals.
Andreas Tsakalof PhD (University of Thessaly, Volos, Greece).
Andreas Tsakalof received the degree in Chemical Engineering in 1977 from Lomonosov Moscow State University of Fine Chemical Technology (Russia) and Ph.D. in Chemistry in 1986 from Russian Academy of Science, Nesmeyanov Institute of Organoelement Compounds (INEOS RAS, Moscow, Russia). In 1998-1999 he was trained in Molecular Toxicology at the University of Surrey, School of Biological Sciences (Guildford, UK) in the framework of the European Marie Curie research fellowship. Nowadays he is Associate Professor of Medical Chemistry at the School of Medicine, University of Thessaly, Greece. Professor A. Tsakalof is European Registered Toxicologist (ERT) by EUROTOX and awarded reviewer from the journals of Toxicology Letters (2011) and Food and Chemical Toxicology (2015). His research interests are nowadays focused on the development and application of new sample preparation and analysis methods in clinical chemistry and toxicology, preparation and use of molecularly imprinted polymers in target separation of bioactive compounds from natural sources.
Constantinos Pistos PhD (West Chester University, West Chester, PA, USA).
Dr. Pistos graduated from the department of pharmacy of the Aristotle University of Thessaloniki (Greece) on 1995, before he pursued his M.Sc. and Ph.D studies, at the Department of Pharmacy of the University of Athens (Greece). On 2001-2002 he continued his research as postdoctoral fellow at the college of pharmacy of the University of Georgia Athens, GA (U.S.A.), before serving as director of a private CRO pharmaceutical company in Greece. Between 2006 and 2012, he possessed the position of Lecturer and by 2012 of Assistant Professor in Toxicology at the School of Medicine of the University of Athens (Greece). By 2015, Dr. Pistos possesses the position of Assistant Professor of Toxicology at the Department of Chemistry at West Chester University of Pennsylvania, U.S.A. He has published fifty-two articles and four book chapters while he presented thirty-five research works in congresses, in the fields of toxicology and pharmaceutical analysis.
Kai Wang, PhD (Frontage Laboratories, Inc., Exton, PA, USA). orcid.org/0000-0003-0157-7496
Dr. Kai Wang is Group Leader of Bioanalytical and Biologics Services at Frontage Laboratories, Inc, a leading global CRO, and has lead more than 100 bioanalytical projects related to the development of pharmaceutical products. Dr. Wang’s current research focus is in the area of bioanalytical method development and validation, including quantitation of small molecule drugs and metabolites, as well as big molecule drugs and biomarkers such as oligonucleotides, proteins, peptides, and glycosaminoglycans. Dr. Wang’s research interest also involves developing bioanalytical methods using novel techniques such as dry blood spot (DBS) sampling, microsampling and analyte derivatization. Dr. Wang earned a doctor of philosophy degree in chemistry from Rutgers University – New Brunswick. He received a bachelor of science degree in chemistry from Nanjing University.
Dionysios Pantazatos, PhD (Takeda Pharmaceuticals, San Diego, CA, USA).
received a BS in Biomedical Engineering from Northwestern University Chicago IL., an MS in Human Genetics from the University of Michigan Ann Arbor, and his PhD from the University of California San Diego. During his graduate studies he applied hydrogen deuterium exchange mass spectrometry (HDXMS) to characterize structure and dynamics of proteins and protein-ligand interactions. He holds one patent in the application of HDXMS for improving protein structure prediction and developed computational methods for determining hydrogen exchange rates from a 3D protein structure and calculating single amide exchange rates from HDX datasets. He completed his postdoctoral training at Harvard Medical School and held a faculty position at Brown Medical School and served as Director of the Center or Biomedical Cancer Research proteomics core.
Morse Faria, PhD (PPD Laboratories, Richmond, VA, USA).
obtained his bachelor degree in Pharmaceutical sciences from Goa University, India in and Master of Pharmacy degree from University of Mumbai, India. He completed his Ph.D. in Pharmaceutical Sciences from Virginia Commonwealth University, USA. He is currently working as a Research Scientist at Pharmaceutical Product Development, USA. Prior to obtaining his Ph.D., Dr. Faria worked as Research Associate at Wockhardt Ltd., Mumbai, India and as a Lecturer in Pharmacy, University of Mumbai, India. He is a reviewer for various bioanalytical journals including Bioanalysis, Journal of Chromatography B and Journal of Pharmaceutical and Biomedical Analysis. Dr. Faria’s main area of research focus is quantitative bioanalysis using liquid chromatography and tandem mass spectrometry (LC-MS/MS). He specializes in bioanalysis of protein molecules (biomarkers and biotherapeutics) from biological specimens to support drug discovery and drug development.
Linzhi Chen, PhD (Boehringer Ingelheim Pharmaceuticals, CT, USA).
Dr. Chen Dr. is a Sr. Research Fellow at Boehringer Ingelheim Pharmaceuticals. He received his Ph.D. in organic chemistry from the University of Mons, Belgium where he studied gas-phase ion chemistry by mass spectrometry. After completed his postdoctoral research on ion-molecule reactions, he began his industry career with 3M Co. where he spend 5 years on metabolite identification/profiling, bioanalysis and pharmacokinetics. He joined Boehringer Ingelheim Pharmaceuticals in 2001 to lead a bioanalytical group in support of small molecule drug development. In recent years he has been providing LC/MS-based bioanalytical support to biotherapeutic development programs, and developed a number of LC/MS assays for various biotherapeutic proteins such as nanobodies, Fabs, bispecifics and mAbs, as well as oligonucleotides. His group also developed immunocapture-LC/MS methodology for simultaneous ADA isotyping and semi-quantitation. His recent interest focuses on LC/MS determination of in vivo biomodifications of biotherapeutics and their impact on PK/PD.
Padmanabhan Eangoor, PhD (Discovery Bioanalysis, Merck & Co, Boston, MA, USA).
Dr. Padmanabhan Eangoor received his Ph.D. in Pharmaceutical Sciences from Mercer University and M.S. in chemistry from Eastern New Mexico University. His Ph.D. work was focused on developing and validating liquid chromatography and tandem mass spectrometry (LC-MS/MS), and immunoassay methods for the clinical diagnosis of paralytic shellfish poisoning. Currently, he is working as a senior scientist in a discovery bioanalytical lab at a leading biopharmaceutical company (Merck & Co.). In his current role, he develops LC-MS/MS and ligand binding assay methods for the quantification of small molecules, proteins, and oligonucleotides in biological matrices for preclinical studies.
William van Dongen, PhD (QPS, Groningen, the Netherlands).
Dr. van Dongen holds a PhD in Biological Mass Spectrometry. He has more than 20 years of experience in the biotechnological and pharmaceutical industry. During this time, William gained a broad experience in characterization and bioanalysis, as well as physicochemical techniques for complex formulation development. Moreover, he acquired significant knowledge of the pharmaceutical drug development process. William has from early on in his career always been fully connected to GXP, as he worked many years as GLP Study Director and currently carries the responsibility of a fully GMP compliant laboratory.
Lake Paul, PhD (Abzena, Bristol, PA,USA).
Dr. Paul manages the Bioconjugation Chemistry team which is split into Process Development (PD), cGMP Bioanalytical and cGMP Bioconjugation manufacturing at Abzena. He oversees the PD bioconjugation activities, edits, designs and reviews qualification strategies for the cGMP Bioanalytical team. For the cGMP manufacturing: preparation of SOPs, batch records and manages the manufacturing floor. Previously he had 11 plus years of protein characterization experience using biophysical and analytical chemistry techniques. He was the former Director of the Biophysical Analysis Lab and also the Purdue Proteomic Facility. He is the author and co-author of 25 plus publications in the areas of protein/particle characterization. Lake earned his BS in Biology from University of Miami (2000). He completed his PhD in Structural Biology and Biophysics at Purdue University in 2007. Following his PhD, he went to the National Institutes of Environmental Health Sciences for his post-doctoral work in mass spectrometric applications to structural biology.
Abhisheak Sharma, B Pharm M Pharm Ph.D (Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA).
Dr. Sharma earned his Ph.D. in pharmacokinetics and metabolism from CSIR-Central Drug Research Institute, Lucknow, India. He is a trained analytical scientist, pharmacokineticist and pharmacist whose research focuses on the in vivo and in vitro preclinical pharmacokinetic studies of new chemical entities and natural products. He is proficient in various approaches to bioanalytical method development and validation of discovery compounds and plant alkaloids in different biological matrices (blood, dried blood spot, plasma, serum, tissue homogenates, and urine) using various analytical techniques (UPLC-MS/MS, UPLC-PDA-MS, and UPLC-PDA/FL). His research interests include translational development of new chemical entities to candidate drugs using PK-PD modeling and simulation approach.
Michel L. Campos, MSc Ph.D (Federal University of Mato Grosso – UFMT, Sinop, Brazil).
Dr. Campos received his MSc and PhD in Pharmaceutical Sciences from Sao Paulo State University “Julio de Mesquita Filho” – Faculty of Pharmaceutical Sciences, Brazil (2015), with part of the research in the Centre for Research in Mass Spectrometry at York University, Canada. He worked as a postdoctoral fellow and substitute professor at Federal University of Paraná, Brazil. He joined the Health Sciences Institute at Federal University of Mato Grosso as an Adjunct Professor in 2018. His major research interests are Clinical Pharmacokinetics, Pharmacokinetics and Pharmacodynamics, Preclinical Testing of New Drugs and Medicines, Metabolites Investigation by High-Resolution Mass Spectrometry, and Development and Validation of Bioanalytical Methods by HPLC and LCMS. Academic experience in Clinical Pharmacology, Clinical Pharmacokinetics applied to Dose Determination, Therapeutic Drug Monitoring and Dose Adjustment of Antibiotics from Pharmacokinetic and Pharmacodynamic parameters.
Yu-Luan Chen, BSc MSc Ph.D (Sunovion Pharmaceuticals, Marlborough, MA, USA).
Dr. Yu-Luan Chen is currently Senior Director, Bioanalytical Sciences, Clinical Pharmacology, Translational Medicines & Early Development. He received his B.Sc degree (Xiamen), M.Sc. degree (Nanjing), and Ph.D. degree from the University of British Columbia (Canada). His expertise includes Bioanalytical Sciences and Analytical Chemistry with special focus in Separation Sciences and LC-MS/MS technologies applying to clinical pharmacokinetics /pharmacodynamics (PK/PD), drug metabolism research, and biomarker assays. Dr. Chen is the editor, Feature Articles for Chinese-American Chemical Society (CACS) Communications, an editorial board member for Journal of Molecular and Applied Bioanalysis, Drug Metabolism Letters, and The Open Spectroscopy Journal. Dr. Chen has published over 50 peer-reviewed papers and three book-chapters. His current research interests include bioanalytical LC-MS/MS method development, bioanalytical method validation, PK/PD sample analysis, in vitro and in vivo drug metabolism (cold and hot approaches), biomarker assays, microsampling technologies, and supporting drug discovery and development from nonclinical exploratory through GLP toxicology, and from clinical Phase I through new drug application further to post-approval commitments.
Tao Niu PhD (Merck Research Laboratories, West Point, PA, USA).
Dr. Niu, is currently a senior scientist in regulated pharmacokinetics at Merck. Dr. Niu is specialized in method development, validation and sample analysis of biological drug candidates using LC-MS in preclinical and clinical studies (GLP/GCP). Prior to joining Merck, Dr. Niu worked on LC-MS/MS method development and validation of pain medications in human oral fluid and synthetic cannabinoids in human urine at Genotox Laboratories. Tao received his PhD in pharmaceutics from University of Houston, with his thesis on gut microflora metabolism of xenobiotics. Dr. Niu also holds an MS in pharmacometrics from University of Maryland, with a focus on population pharmacokinetics of unfractionated heparin in pediatrics. Dr. Niu’s main research interest is to investigate the impact of bioanalytical assay format on the pharmacokinetics and pharmacodynamics of protein/peptide therapeutics.
Mohammad Sharif Khan PhD (Thayer School of Engineering, Dartmouth College, Hanover, NH, USA).
Dr. Khan is working at Thayer school of engineering at Dartmouth College. For the last 10 years, he has contributed to different fields of analytical chemistry and separation science. His primary interest in on bio-analytical chemistry, multidimensional chromatography, mass spectrometry, metabolomics and omics data analysis. Dr. Khan is the inventor of pressure tuning GC×GC (Pressure tuning comprehensive two dimensional gas chromatography). This innovation was the spotlight for the LCGC article in North America, Europe and Asian edition. Mohammad has also worked on green sample preparation, supercritical extraction, optimization and identification of bioactive molecules from complex matrices and unconventional FTIR, TLC based fingerprinting. Mohammad is recently working on the application of high-resolution omics techniques for clinical application like VOCs from infectious bacteria or breath VOCs to understand the host-microbes interaction mechanism for disease diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. Mohammad has more than 1000 ciation with a h-index of 10. Mohammad love to play and watch cricket at spare time, like to explore new place and outdoor activity.
Ben M. de Rooij PhD (Avans University of Applied Sciences, Breda, the Netherlands).
Ben de Rooij earned his Ph.D. in analytical toxicology from the Free University of Amsterdam. After this he was appointed as Study Director and Project Manager in different Contract Research Organizations before he entered Avans University of Applied Sciences (Avans UAS). In this UAS he coordinates the teaching program Forensic Laboratory Science and developed the bioanalytical part of the program. Next to teaching Ben is responsible for research projects in the forensic and clinical field. The mean focus in his career is the development of chromatography-mass spectrometry methods in various biological matrices for clinical, pharmaceutical and forensic applications.
Mark Shapiro MSc (MCS Pharma Consulting LLC, Stokesdale, NC, USA).
Mark Shapiro is President and Principle Consultant at MCS Pharma Consulting, specializing in analytical chemistry. With 40+ years in the pharmaceutical industry in Analytical R&D and Quality Control/Operations, he is highly experienced in pharmaceutical analysis, drug quality for APIs and final dosage forms, and USP/ICH compliance. Mark has held Senior Director, Director, or Managerial positions in PharmaCore/Cambrex, Noramco, and Warner-Lambert/Pfizer; and senior analytical research positions in McNeil Consumer Products Company and (earlier) other smaller pharmaceutical and nutraceutical companies. Mark began his career as a pharmacist. He holds an MS degree in Pharmaceutical Chemistry from Lehigh University and a BS in Pharmacy from University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy & Science). He currently lives in north-central North Carolina with his wife of 36+ years and enjoys amateur astronomy. He has over 50 publications/presentations.
Chukwunonso Nwabufo MSc (Gilead Sciences Alberta ULC, Edmonton AB, Canada).
Chukwunonso is an accomplished Pharmaceutical Scientist with over 4 years of experience in drug development across academia and the pharmaceutical industry. He provides an extensive range of analytical chemistry services to support drug development programs and was recently involved in the development of Remdesivir. He has received over 10 awards for research, academic, and leadership accomplishments. His current research interest is on the enhancement of the clinical efficacy and effectiveness of respiratory and neurological medicines. Pharmacokinetics, Pharmacodynamics, and Drug Metabolism Community. Prior to joining Gilead Sciences, he completed an MSc in Pharmacy with distinction at the University of Saskatchewan with a research focus on the preclinical development of novel therapeutic agents for Parkinson’s disease. Chukwunonso completed an undergraduate program in Biochemistry at the University of Benin with First class honors and thesis research that was primarily focused on the effect of Hibiscus Sabdariffa extract on the reproductive hormones of male Wistar rat.
Yongle Pang PhD (GlaxoSmithKline, Collegeville, PA, USA).
Dr. Pang is currently a bioanalyst in the discovery DMPK department at GSK (PA, USA). His job duty includes the design and delivery of fit-for-purpose bioanalytical data to support early discovery in vivo and in vitro projects. Before joining GSK, he was a staff scientist in the regulated bioanalysis department at Covance (WI, USA). He was responsible for method development and method validation for a variety of drug candidates. Dr. Pang is a graduate of Michigan State University (Ph.D. in Chemistry, MI, USA), where he developed enzyme-containing membranes for rapid monoclonal antibody digestion prior to mass spectrometry analysis. He has extensive experience in LC/MS-based small molecule and large molecule bioanalysis in the GLP and non-GLP settings. He has a great passion for bioanalysis and contributes to various peer-reviewed publications. He is also an active reviewer for journals in the analytical chemistry area.